Evidence map›Paper›PMID 18558452›Full record

ReviewAdvanced drug delivery reviews2008

Magnetic nanoparticles in MR imaging and drug delivery.

Conroy Sun, Jerry S H Lee, Miqin Zhang

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 505 papers.

0numbers the graph read from it
0cells of the map it votes in
505citing papers in PubMed
61.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

505 citing papers in PubMed, 2,543 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Molecules (Basel, Switzerland) · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Embracing cancer immunotherapy with manganese particles.Cellular oncology (Dordrecht, Netherlands) · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Review

445 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Conroy SunDepartment of Materials Science and Engineering, University of Washington, Seattle, WA 98195, USA.
Jerry S H LeeOffice of Technology and Industrial Relations, National Cancer Institute, Bethesda, MD 20892, USA.
Miqin ZhangDepartment of Materials Science and Engineering, University of Washington, Seattle, WA 98195, USA.
University of Washington · USNational Cancer Institute · US

Funding

Multifuctional Nanovector For Diagnosis And Treatment Of Pediatric Brain CancerR01EB006043 · NIBIB · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2007 to 2010
$1.6M
Nanovectors For Brain Tumor Diagnosis And TreatmentR01CA134213 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2007 to 2011
$1.5M
Nanotechnology Platform for Pediatric Brain Cancer Imaging and TherapyR01CA119408 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2005 to 2009
$1.4M
NCI NIH HHS R01 CA119408NCI NIH HHS R01CA119408NCI NIH HHS R01 CA134213NCI NIH HHS R01CA134213NIBIB NIH HHS R01 EB006043NIBIB NIH HHS R01EB006043
6 · The paper itself

Abstract

Magnetic nanoparticles (MNPs) possess unique magnetic properties and the ability to function at the cellular and molecular level of biological interactions making them an attractive platform as contrast agents for magnetic resonance imaging (MRI) and as carriers for drug delivery. Recent advances in nanotechnology have improved the ability to specifically tailor the features and properties of MNPs for these biomedical applications. To better address specific clinical needs, MNPs with higher magnetic moments, non-fouling surfaces, and increased functionalities are now being developed for applications in the detection, diagnosis, and treatment of malignant tumors, cardiovascular disease, and neurological disease. Through the incorporation of highly specific targeting agents and other functional ligands, such as fluorophores and permeation enhancers, the applicability and efficacy of these MNPs have greatly increased. This review provides a background on applications of MNPs as MR imaging contrast agents and as carriers for drug delivery and an overview of the recent developments in this area of research.

Indexed as

Drug Delivery SystemsNanoparticlesAnimalsHumansMagnetic Resonance ImagingMagneticsTissue Distribution

Identifiers

PMID18558452
PMCPMC2702670
OpenAlexW2132005699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.